biotechnews

Liminatus Pharma Expands into Cryptocurrency and Blockchain Sector

July 27, 2025 — In a surprising move, Liminatus Pharma, a clinical-stage biopharmaceutical company known for its cancer immunotherapy research, has announced its entry into the cryptocurrency and blockchain space. The company aims to integrate decentralized technologies to enhance transparency in clinical trials, secure patient data, and streamline global collaborations.

Liminatus is reportedly exploring the launch of a blockchain-powered platform that will allow secure sharing of research data and real-time trial updates. Additionally, the firm is considering the use of cryptocurrency-based incentives to encourage patient participation and data sharing in trials.

This strategic expansion marks a significant diversification for the pharma firm, signaling the increasing convergence of healthcare and Web3 technologies. Investors and analysts are closely watching how this move could influence both biotech and blockchain markets.

#Liminatus #blockchain #CryptoInnovation #BiotechNews

$XRP
$SOL
$BTC

CASSAVA SCIENCES CLEARED IN FRAUD CASE, RISKS REMAIN

A U.S. court dismissed fraud charges against Hoau-Yan Wang, Cassava’s ex-adviser, over alleged NIH grant data fabrication tied to Alzheimer’s drug simufilam. While the ruling ends criminal proceedings, SEC civil actions and investor suits persist, keeping pressure on Cassava’s credibility and Phase 3 outlook. The verdict offers relief but not full redemption for the embattled biotech.

#BiotechNews #CassavaSciences